A best evidence topic was written according to a structured protocol. The question addressed was whether sutureless aortic valves have a clinical and haemodynamic benefit in high-risk patients with aortic valve disease. A total of 307 papers were found using the reported searches; of which, six represented the best evidence to answer the clinical question. The authors, date, journal, study type, population, main outcome measures and results are tabulated. The studies found analysed the outcomes of sutureless aortic valve implantation in high-risk patients undergoing aortic valve replacement. Reported measures included mortality; post-operative complications namely stroke, renal failure, endocarditis and bleeding; valve deployment, cardiopulmonary bypass (CPB) and aortic cross-clamp (ACC) times; echocardiographic assessment of paravalvular leaks (PVLs) and valve haemodynamics; and symptomatic functional class. Hospital mortality ranged between 3.1 and 12.5% and long-term mortality ranged between 3.1 and 10%. Incidence of PVL was found to be between 0.0 and 11%. Stroke was observed in 0.7%, renal failure in 3.1%, prosthetic valve endocarditis in 2.1-3.1% and major bleeding in 3.1%. The valve deployment time was 9-21 min, CPB time 35-111 min and ACC time 17-70 min. Short-term mean and peak valve gradients were in the ranges of 10-11 and 18-22 mmHg, respectively, reducing to 8-9 and 16.4-19 mmHg, respectively, at follow-up. Owing to the lack of comparative studies analysing the outcomes of sutureless and conventional aortic valves, we compared these results with the recently published PARTNER Trial (Transcatheter vs. Surgical Aortic-Valve Replacement in High-Risk Patients), and it can be shown that the outcomes of sutureless aortic valves compare favourably with conventional valves in terms of mortality, neurological deficit, renal failure and post-operative bleeding. However, there is increased incidence of endocarditis and PVLs, together with raised mean valve gradients, perhaps owing to the mechanical properties and deployment techniques of sutureless aortic valves.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This protocol is fully described in ICVTS [1] . Aortic valve replacement (AVR) in high-risk patients carries a significant risk of mortality and morbidity and consequently alternative options have been considered in this population to minimize this risk. The recently published PARTNER Trial (Transcatheter vs. Surgical Aortic-Valve Replacement in High-Risk Patients) [2] consisted of a high-risk patient population of 351 undergoing surgical AVR in the control arm. Thirty-day and 1-year mortality were reported at 6.5 and 26.8%; neurological events at 2.4 and 4.3%; renal replacement therapy at 3 and 6.5%; endocarditis at 0.3 and 1% and major bleeding at 19.5 and 25.7%, respectively. At 1-year follow-up, the mean valve gradient was measured at 11.5 mmHg and the mean valve area at 1.44 cm 2 . Incidence of moderate or severe paravalvular leak (PVL) at 30 days and 1 year were 0.9 and 1.9%, respectively. The use of sutureless aortic valves has been proposed as a viable option in this high-risk patient population.
Clinical scenario
A symptomatic 70-year old lady with shortness of breath on minimal exertion is referred for consideration of AVR. She had successfully undergone coronary artery bypass grafts 8 years previously and has a diagnosis of chronic obstructive pulmonary disease. Echocardiography demonstrates peak aortic valve gradient of 71 mmHg, aortic valve area of 0.7 cm 2 and left ventricular ejection fraction of 48%. Computed tomography aortogram reveals mild calcification in the ascending aorta. Based on the logistic EuroSCORE of 36.6%, you contemplate the options for this high-risk AVR. 
Search outcome
Three hundred and seven articles were found using the reported search strategy. From these, six articles provided the best evidence to answer the question. These are presented in Table 1 .
RESULTS
Martens et al. [3] conducted a multi-centre clinical trial of 140 highrisk patients undergoing sutureless AVR. They reported a 30-day mortality of 3.6%, with valve-related deaths in 1.4% and a longterm follow-up mortality of 9.3%, again with valve-related deaths in 1.4%. The mean cardiopulmonary bypass (CPB) time and aortic cross-clamp (ACC) times were 84.9 and 58.1 min, respectively. Significant PVLs were observed in 2.1% post-operatively and 0.7% during follow-up, with all patients undergoing redo AVR. Minor PVL was observed in 2.1%. Post-operative complications included stroke in 0.7% and prosthetic valve endocarditis in 2.1%. The average peak aortic valve gradient was 20.34 mmHg at discharge and 16.4 mmHg at 11-14-month follow-up and NYHA classes of I and II were both observed in 49.4% at follow-up. Flameng et al. [4] conducted a prospective study of 32 high-risk patients undergoing sutureless AVR. They reported no operative mortality and three deaths during follow-up, all of non-cardiac causes. In isolated AVR, the median CPB time was 35 min and the median ACC time was 17 min. Post-operative complications included prosthetic valve endocarditis requiring re-operation in one patient, atrioventricular block requiring permanent pacemaker in one patient, temporary renal dialysis in one patient and re-exploration for bleeding in one patient. Mild PVL was observed in 16% both at discharge and at 6-month follow-up and in 6% at 12-month follow-up. Moderate PVL was observed only in 3% at 6-month follow-up. Mean and peak pressure gradients were 11 and 22 mmHg at discharge, 10 and 18 mmHg at 6 months and 9 and 19 mmHg at 12 months, respectively. NYHA classes of I and II were both observed in 48% at 12-month follow-up.
Breitenbach et al. [5] reported the outcomes in 32 high-risk patients undergoing sutureless AVR in a prospective multi-centre study. Their only hospital mortality was as a result of a pulmonary embolus post-operatively and another patient died during follow-up as a result of bronchial carcinoma. The mean valve deployment time, CPB time and ACC time were 21, 111 and 70 min, respectively. One mild and two moderate cases of PVL were observed at discharge. At 3-6-month follow-up, there were two cases of mild regurgitation, reduced to one case at 11-14-month follow-up. After 2 years, NYHA classes of I, II and III were observed in 67, 25 and 8%, respectively. One patient underwent redo AVR for prosthetic valve endocarditis.
Aymard et al. [6] conducted a clinical trial of 28 consecutive high-risk patients undergoing sutureless AVR. There were two 30-day and follow-up mortalities, respectively. The mean deployment time, operation time, CPB time and ACC time were 9, 135, 58 and 39.8 min, respectively. There was a significant increase in aortic valve area (2.1 vs. 0.6 cm 2 , P < 0.002) and a significant reduction in mean pressure gradient (10.4 vs. 44 mmHg, P < 0.002). PVL was observed in 11% and redo AVR performed in 3.5% for significant PVL at 3 months. A permanent pacemaker was required in 18.5%.
Martens et al. [7] conducted a prospective study of 32 high-risk patients undergoing sutureless AVR. Ninety-day mortality was reported at 12.5%, with normal valve function observed in all cases. The valve deployment time was reported at 9 min and in cases of isolated AVR, CPB and ACC times were 87 and 55 min, respectively. There were no incidences of intra-operative PVL; however, one mild PVL was noted at 6-month follow-up, later undetectable at 12 months. The peak valve gradient remained unchanged at 18 mmHg after 6 months in comparison to discharge.
Shrestha et al. [8] conducted a multi-centre trial of 30 consecutive high-risk patients undergoing sutureless AVR. One patient died of sudden cardiac death in hospital; however, no valvular pathology was detected. Follow-up mortality at 12 months was 10%. For isolated AVR, mean CPB and ACC times were 46.4 and 29 min, respectively. There was only one observed case of the following post-operative complications: cardiac tamponade, atrioventricular block, wound infection, gastrointestinal bleed and peripheral thromboembolism. At 12-month follow-up, mild PVL was detected in two patients and NYHA classes of I and II were observed in 57 and 39%, respectively.
